Literature DB >> 11689632

Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptors.

S Pontow1, L Ratner.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) infection in vivo is dependent upon the interaction of the viral envelope glycoprotein gp120 with CC chemokine receptor 5 (CCR5) or CXC chemokine receptor 4 (CXCR4). To study the determinants of the gp120-coreceptor association, we generated a set of chimeric HIV-1 coreceptors which express all possible combinations of the four extracellular domains of CCR5 and CXCR4. Stable U87 astroglioma cell lines expressing CD4 and individual chimeric coreceptor proteins were tested against a variety of R5, X4, and R5X4 envelope glycoproteins and virus strains for their ability to support HIV-1-mediated cell fusion and infection, respectively. Each of the cell lines promoted fusion with cells expressing an HIV envelope glycoprotein, except for U87.CD4.5455, which presents the first extracellular loop (ECL1) and flanking sequences of CXCR4 in the context of CCR5. However, all of the chimeric coreceptors allowed productive infection by one or more of the viral strains tested. Viral phenotype was a predictive factor for the observed activity of the chimeric molecules; X4 and R5X4 HIV strains utilized a majority of the chimeras, while R5 strains were limited in their ability to infect cells expressing these chimeric molecules. The expression of CCR5 ECL2 within the CXCR4 backbone supported infection by an R5 primary isolate, but no chimeras bearing the N terminus of CCR5 exhibited activity with R5 strains. Remarkably, the introduction of any CXCR4 domain into the CCR5 backbone was sufficient to allow utilization by multiple X4 strains. However, critical determinants within ECL2 and/or ECL3 of CXCR4 were apparent for all X4 viruses upon replacement of these domains in CXCR4 with CCR5 sequences. Unexpectedly, chimeric coreceptor-facilitated entry was blocked in all cases by the presence of the CXCR4-specific inhibitor AMD3100. Our data provide proof that CCR5 contains elements that support usage by X4 viral strains and demonstrate that the gp120 interaction sites of CCR5 and CXCR4 are structurally related.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689632      PMCID: PMC114737          DOI: 10.1128/JVI.75.23.11503-11514.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Polymorphisms in the CCR5 genes of African green monkeys and mice implicate specific amino acids in infections by simian and human immunodeficiency viruses.

Authors:  S E Kuhmann; E J Platt; S L Kozak; D Kabat
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use.

Authors:  D Schols; J A Esté; C Cabrera; E De Clercq
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  HIV-1 gp120 induces an association between CD4 and the chemokine receptor CXCR4.

Authors:  S Ugolini; M Moulard; I Mondor; N Barois; D Demandolx; J Hoxie; A Brelot; M Alizon; J Davoust; Q J Sattentau
Journal:  J Immunol       Date:  1997-09-15       Impact factor: 5.422

4.  CCR5 HIV-1 coreceptor activity. Role of cooperativity between residues in N-terminal extracellular and intracellular domains.

Authors:  Z Wang; B Lee; J L Murray; F Bonneau; Y Sun; V Schweickart; T Zhang; S C Peiper
Journal:  J Biol Chem       Date:  1999-10-01       Impact factor: 5.157

5.  In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.

Authors:  G Scarlatti; E Tresoldi; A Björndal; R Fredriksson; C Colognesi; H K Deng; M S Malnati; A Plebani; A G Siccardi; D R Littman; E M Fenyö; P Lusso
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

6.  A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5.

Authors:  M Farzan; H Choe; L Vaca; K Martin; Y Sun; E Desjardins; N Ruffing; L Wu; R Wyatt; N Gerard; C Gerard; J Sodroski
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

7.  Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry.

Authors:  T Dragic; A Trkola; S W Lin; K A Nagashima; F Kajumo; L Zhao; W C Olson; L Wu; C R Mackay; G P Allaway; T P Sakmar; J P Moore; P J Maddon
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

8.  Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1.

Authors:  G E Rabut; J A Konner; F Kajumo; J P Moore; T Dragic
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

9.  CXCR4 sequences involved in coreceptor determination of human immunodeficiency virus type-1 tropism. Unmasking of activity with M-tropic Env glycoproteins.

Authors:  Z X Wang; J F Berson; T Y Zhang; Y H Cen; Y Sun; M Sharron; Z H Lu; S C Peiper
Journal:  J Biol Chem       Date:  1998-06-12       Impact factor: 5.157

10.  Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100.

Authors:  B Labrosse; A Brelot; N Heveker; N Sol; D Schols; E De Clercq; M Alizon
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

View more
  15 in total

1.  Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.

Authors:  Cajetan Dogo-Isonagie; Son Lam; Elena Gustchina; Priyamvada Acharya; Yongping Yang; Syed Shahzad-ul-Hussan; G Marius Clore; Peter D Kwong; Carole A Bewley
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

2.  Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.

Authors:  C Pastore; R Nedellec; A Ramos; S Pontow; L Ratner; D E Mosier
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  Antiviral activity of a Rac GEF inhibitor characterized with a sensitive HIV/SIV fusion assay.

Authors:  Suzanne Pontow; Brooke Harmon; Nancy Campbell; Lee Ratner
Journal:  Virology       Date:  2007-07-19       Impact factor: 3.616

4.  Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Rebecca Nedellec; Alejandra Ramos; Oliver Hartley; John L Miamidian; Jacqueline D Reeves; Donald E Mosier
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

5.  Design and synthesis of small molecule-sulfotyrosine mimetics that inhibit HIV-1 entry.

Authors:  Cajetan Dogo-Isonagie; Su-Lin Lee; Katheryn Lohith; Hongbing Liu; Sivakoteswara R Mandadapu; Sabrina Lusvarghi; Robert D O'Connor; Carole A Bewley
Journal:  Bioorg Med Chem       Date:  2016-03-03       Impact factor: 3.641

6.  Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody.

Authors:  Shi-Hua Xiang; Michael Farzan; Zhihai Si; Navid Madani; Liping Wang; Eric Rosenberg; James Robinson; Joseph Sodroski
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step.

Authors:  Brooke Harmon; Nancy Campbell; Lee Ratner
Journal:  PLoS Pathog       Date:  2010-06-17       Impact factor: 6.823

8.  The human immunodeficiency virus type 1 envelope confers higher rates of replicative fitness to perinatally transmitted viruses than to nontransmitted viruses.

Authors:  Xiaohong Kong; John T West; Hong Zhang; Danielle M Shea; Tendai J M'soka; Charles Wood
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

9.  Actin cytoskeletal reorganizations and coreceptor-mediated activation of rac during human immunodeficiency virus-induced cell fusion.

Authors:  S E Pontow; N Vander Heyden; S Wei; L Ratner
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Induction of the Galpha(q) signaling cascade by the human immunodeficiency virus envelope is required for virus entry.

Authors:  Brooke Harmon; Lee Ratner
Journal:  J Virol       Date:  2008-07-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.